Nathalie Joly VP Business Development at MImAbs SAS is on-site today at the 11th Annual Immuno-Oncology 360° Summit in Boston.

She brings extensive experience in antibody generation, bioproduction, and engineering, including Antibody-Drug Conjugates (ADCs) and other advanced therapeutic platforms. Nathalie also provides insights into how MImAbs SAS ensure seamless preclinical development and efficient transfer to clinical phases, offering expert support at every stage.

Looking forward to connecting with you.

#IO360 #IO360Summit #Biotech #ImmunoOncology #Antibody #AntibodyDrugConjugates #AntibodyGeneration